ライフサイエンスコーパス: DMF

1 o the fuel precursor 2,5-dimethyl furan (2,5-DMF).

2 st molecules, such as N,N-dimethylformamide (DMF).

3 on of biosensors into digital microfluidics (DMF).

4 tegration of ECL with digital microfluidics (DMF).

5 queous desulfurization system (Fe(III/II)-IL/DMF).

6 conditions examined (up to 140 degrees C in DMF).

7 and embedded sensors: "plug-n-play DMF" (PnP-DMF).

8 r solvothermal treatment at 200 degrees C in DMF.

9 rs of disease activity during treatment with DMF.

10 AP recapitulated the antifibrotic effects of DMF.

11 the hydrolytic cleavage of the amide bond in DMF.

12 s applicable to all biosensors integrated to DMF.

13 teine 38 being essential for the activity of DMF.

14 in the compound (K[222-crypt])4 [Sn14 Ni(CO)]DMF.

15 by iron(tetramesitylporphyrin) (Fe(TMP)) in DMF.

16 re collected at baseline and 12 months after DMF.

17 hione (GSH) abrogated ULBP2/5 upregulated by DMF.

18 ransfer and TU to stabilize metal cations in DMF.

19 at baseline, and 1, 3, 6 and 12 months after DMF.

20 nase IRAK4 as a principal cellular target of DMF.

21 on going from nonpolar toluene to more polar DMF.

22 g were associated with the rate of change in dmfs.

23 t [Ni(II)(2)Dy(III)(2)L(4)(DMF)(6)] 2(OTf) 2(DMF) (1) promotes the domino reaction of furfural and am

24 ated with the integration of biosensors into DMF: (1) complete removal of the droplet containing the

25 o N-alkyl and N-acyl analogues (RX, NaHCO(3)/DMF/100 degrees C) in high overall yields.

26 2 (L3)(H2 O)2 ]n (NJU-Bai 42), and [Cu2 (L4)(DMF)2 ]n (NJU-Bai 43) were prepared and we observed that

27 rmal crystallisation of a new MOF [Yb2(BDC)3(DMF)2]H2O (BDC=benzene-1,4-dicarboxylate and DMF=N,N-dim

28 diiron(II) complex, [Fe(2)(N-Et-HPTB)(NO)(2)(DMF)(2)](BF(4))(3) (2) with [{FeNO}(7)](2) formulation a

29 acid as modulators: [Bi(2)(cpb)(acetato)(2)(dmf)(2)].2dmf CTH-6 forms a rtl-net; 2(H(2)NMe(2))[Cu(2)

30 H-11, show kgd-nets; [Cu(2)(cpb)(acetato)(2)(dmf)(2)].2dmf, CTH-12, forms a mixed coordination and hy

31 solid-organic sodium ion electrolyte NaClO4 (DMF)3 (DMF=dimethylformamide) is described.

32 on cooling, it resolidifies as solid NaClO4 (DMF)3 , permitting melt casting of the electrolyte into

33 Pressed pellets of microcrystalline NaClO4 (DMF)3 exhibit a conductivity of 3x10(-4) S cm(-1) at roo

34 The crystal structure of NaClO4 (DMF)3 reveals parallel channels of Na(+) and ClO4(-) ion

35 osyl diiron(II) complex, [Fe2(N-Et-HPTB)(NO)(DMF)3](BF4)3 (2).

36 yl diiron(II) complex, [Fe(2)(N-Et-HPTB)(NO)(DMF)(3)](BF(4))(3) (1) (N-Et-HPTB is the anion of N,N,N'

37 iron(II, III) complex, [Fe(2)(N-Et-HPTB)(OH)(DMF)(3)](BF(4))(3) (3).

38 perlattice of monodisperse [Cd54Se32(SePh)48(dmf)4](4-) nanoclusters; the second is a unique porous C

39 H-7 forms a kgd-net; [Fe(4)(cpb)(acetato)(2)(dmf)(4)] CTH-8 and [Co(4)(cpb)(acetato)(2)(dmf)(4)] CTH-

40 )(dmf)(4)] CTH-8 and [Co(4)(cpb)(acetato)(2)(dmf)(4)] CTH-9 are isostructural and form yav-nets; 2(HN

41 RFS], 29%; distant metastasis-free survival [DMFS], 53%; prostate cancer-specific survival [PCSS], 78

42 bimetallic catalyst [Ni(II)(2)Dy(III)(2)L(4)(DMF)(6)] 2(OTf) 2(DMF) (1) promotes the domino reaction

43 y basal prostate cancers (10-year bRFS, 39%; DMFS, 73%; PCSS, 86%; OS, 80%) and luminal A prostate ca

44 minal A prostate cancers (10-year bRFS, 41%; DMFS, 73%; PCSS, 89%; OS, 82%).

45 h ferrocenoyl chloride in dimethylformamide (DMF), a regioselective acylation occurred.

46 ormation of Co-BTTri (Co3[(Co4Cl)3(BTTri)8]2.DMF), a sodalite-type metal-organic framework.

47 In dimethylformamide (DMF), a solvent that disrupts hydrogen bonds, the ReDAC/

48 With DMF, a solvent-induced change in HAT selectivity was obs

49 In addition, DMF abrogated TGFbeta/Akt1 mediated inhibitory phosphory

50 tudies thus identify a proteomic hotspot for DMF action that constitutes a druggable protein-protein

51 Our results suggest that DMF acts on specific memory and effector T cell subsets

52 supporting the notion that the electrophile, DMF, acts via covalent modification.

53 be positioned between digital microfluidics (DMF) addressing each droplet individually using 2D array

54 ifying enzyme, was significantly enhanced by DMF administration in kidney.

55 Following oral DMF administration, central nervous system (CNS) tissue

56 DMF also modulated B-cell MHC II expression and reduced

57 e by the therapeutic drug dimethyl fumarate (DMF) also promotes ULBP2/5 surface expression.

58 need, we examined whether dimethyl fumarate (DMF), an anti-inflammatory drug already in clinical use

59 urements) between a negligible value for Dy2-DMF and 76 cm(-1) for Dy2-CH3CN.

60 he addition of trifluoroethanol (TFE), DMSO, DMF and acetone, uniform fiber-like nanoparticles from P

61 Coumaphos, DMF and DMPF were detected in honey in the range 6-36 ug

62 and two transformation products of amitraz (DMF and DMPF), were quantified at higher levels in wax a

63 PY to the chlorin moiety in both toluene and DMF and exhibits intense fluorescence of chlorin upon ex

64 Upon removal of DMF and H2O solvent molecules, the compound undergoes a

65 high-throughput screening (HTS) methodology, DMF and NaHCO3 were rapidly identified as the most effec

66 se results reveal a new molecular target for DMF and show that a clinically approved drug inhibits M1

67 high risk of PML, were switched from NTZ to DMF and underwent neurological and 3T MRI monitoring for

68 and chronic treatment with dimethylfumarate (DMF) and BHB reduced the tactile allodynia.

69 )benzene (H3BTTri) in N,N-dimethylformamide (DMF) and methanol leads to the formation of Co-BTTri (Co

70 adical (CumO(*)) with N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA) was studied by lase

71 ce (pK(a) values ranging from 3.4 to 13.5 in DMF) and the applied potential.

72 at the combination of N,N-dimethylformamide (DMF) and TU has the remarkable ability to form intermedi

73 ere), mOFC/vmPFC, or dorsomedial prefrontal (DMF), and a comparison group of healthy age- and educati

74 hyl acetate, acetone, alcohol, acetonitrile, DMF, and DMSO, identify complex solvent systems, as well

75 ctivity for Br-capped acrylate chain ends in DMF, and moderate activity toward C-F bonds at room temp

76 DISCUSSION: DMF appeared generally safe and no carryover PML among i

77 Our findings indicate that effects of DMF are facilitated by inhibiting pro-inflammatory NFkap

78 ulfurizer, Fe(II) and N,N-dimethylformamide (DMF) are introduced to Fe(III)-IL to construct a new non

79 ng sulforaphane (SFN) and dimethyl fumarate (DMF), are unable to induce a similar response.

80 domonas, and Alcaligenes have evolved to use DMF as a sole carbon and nitrogen source for growth via

81 his study was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and

82 This study supports the use of DMF as a treatment for SSc dermal fibrosis.

83 of dioxygen catalyzed by iron porphyrins in DMF as an example, decreasing [HA] 10-fold lowers etaeff

84 These results establish DMF as an NFkappaB inhibitor with anti-tumor activity th

85 itially coordinated to Yb(3+) is replaced by DMF as the reaction progresses.

86 ice daily), or open-label dimethyl fumarate (DMF) as a reference.

87 loromethane (DCM) and N,N-dimethylformamide (DMF) as solvents) and relies on the utilization of the g

88 e by replacing water with dimethylformamide (DMF) as the solvent during the synthesis.

89 ylacetamide (DMA) and N,N-dimethylformamide (DMF), as the background electrolyte (BGE) to improve the

90 ploying K2CO3 as a base in refluxing THF and DMF at 80 degrees C, respectively, delivers 2-aroylbenzo

91 ar Heck coupling in the presence of K2CO3 in DMF at 80-140 degrees C.

92 using Selectfluor in the presence of CsF in DMF at room temperature for 15-60 min provided beta-keto

93 s with the treatment with sodium ethoxide in DMF at room temperature provided highly substituted trie

94 step single-pot synthesis occurs smoothly in DMF at rt.

95 ght, breastfeeding and maternal smoking with dmfs at baseline and over time (trajectories) were asses

96 nd maternal smoking were not associated with dmfs at baseline.

97 thin films processed from dimethylformamide (DMF)-based solutions to which either no additive, dimeth

98 nt-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9

99 Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid ester (FAE) th

100 We show that DMF blocks IRAK4-MyD88 interactions and IRAK4-mediated c

101 We found that DMF blocks the profibrotic effects of transforming growt

102 shelf agent, appears to be a redox analog of DMF, but its immunomodulatory properties have not been p

103 nthesized and used a novel chemical probe of DMF by incorporating an alkyne functionality and found t

104 Instead we show that DMF can inhibit the E2 conjugating enzymes involved in K

105 tion of benzyl bromide and sodium hydride in DMF can lead to the formation of an amine side product,

106 Fe(III/II)-IL/DMF can remove hydrogen sulfide and can be regenerated t

107 Baseline mean dmfs/caries prevalence equaled 19.9/86.5% for the INT gr

108 Combined treatment with ABT-199 and DMF caused synergistic cell death specifically in CTCL c

109 s Dy2(INO)4(NO3)22 solvent (solvent=DMF (Dy2-DMF), CH3CN (Dy2-CH3CN)), thereby switching the effectiv

110 al (VLF) cortex and the dorsomedial frontal (DMF) cortex appear to control vocalizations.

111 ating an alkyne functionality and found that DMF covalently modifies p65, with cysteine 38 being esse

112 We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate reacts wi

113 ges are (1) delivering biological samples to DMF devices and (2) accurately controlling temperatures

114 fabricated into the ITO-coated top plates of DMF devices, allowing for the generation of light from e

115 In PnP-DMF, devices are designed to allow for rapid and seamles

116 Although DMF did not eliminate the possibility of disease reactiv

117 By sweep 4, the predicted mean dmfs difference was 1.73 between children with low and h

118 It consists of a digital microfluidic (DMF) diluter chip, an actuation element, a detector elem

119 n (4-nitrophenol and [DMF.H(+)](CF3SO3(-))) (DMF = dimethyl-formamide) or electron (decamethylferroce

120 nzimidazolyl))-2-hydroxy-1,3-diaminopropane; DMF = dimethylformamide) with [Fe(II){FeNO}(7)] formulat

121 rganic sodium ion electrolyte NaClO4 (DMF)3 (DMF=dimethylformamide) is described.

122 agent, N,N-dimethylformamide dimethylacetal (DMF-DMA) and tetramethylammonium hydroxide (TMAH) as met

123 Buffered DMF:DMF(H)(+) mixtures afforded an increase in the catal

124 We show here that dimethyl fumarate (DMF) dose-dependently induces mitochondrial biogenesis a

125 ore correlated with changes in ECC severity (dmfs) during onset than progression.

126 the phases Dy2(INO)4(NO3)22 solvent (solvent=DMF (Dy2-DMF), CH3CN (Dy2-CH3CN)), thereby switching the

127 We propose that DMF-ECL represents a valuable new tool in the microfluid

128 We found that DMF effectively blocks NFkappaB activity in multiple bre

129 f the TU-metal chloride complex formed after DMF evaporation is critical to prevent volatilization of

130 e in preventing the collapse of pores during DMF evaporation.

131 The inhibitory effect of 4-OI and DMF extends to the replication of several other pathogen

132 rylmethyl bromides using t-BuOK as a base in DMF, followed by Pd(0)-mediated intramolecular Heck coup

133 methodology, based on digital microfluidics (DMF), for rapid determination of individual alterations

134 for fumarate-based therapeutics that include DMF, for the treatment of multiple sclerosis.

135 rollable synthesis of N,N-dimethylformamide (DMF) from dimethylamine and CO(2)/H(2) via blocking reac

136 n at -75 degrees C followed by reaction with DMF gave 2-formyl-4-chloro-3-fluoropyridine 10 regiosele

137 g twice-daily group, and 4.78+/-22.05 in the DMF group.

138 nib 75-mg twice-daily group, and 0.20 in the DMF group.

139 When using dimethylformamidium, DMF(H)(+), the mechanism of H2 formation by 1 changes fr

140 toward different proton (4-nitrophenol and [DMF.H(+)](CF3SO3(-))) (DMF = dimethyl-formamide) or elec

141 framework Co-BDTriP (Co3[(Co4Cl)3(BDTriP)8]2.DMF; H3BDTriP = 5,5'-(5-(1H-pyrazol-4-yl)-1,3-phenylene)

142 Administration of DMF has a protective potential against CsA nephrotoxicit

143 ndent mammosphere formation, indicating that DMF has anti-cancer stem cell properties.

144 itu amine functionalized TMU-60 [Zn(OBA)(L*).DMF] has the potential of converting to a conductor due

145 The automation component of DMF have pushed the barriers of this "lab-on-chip" techn

146 (PFS), and distant metastasis-free survival (DMFS) (Hazard Ratios [HRs] = 3.5, 3.1, and 3.8, respecti

147 SS (Hazard Ratio [HR] = 2.30, p = 0.006) and DMFS (HR = 1.78, p = 0.041, respectively).

148 sented here highlight the versatility of PnP-DMF, illustrating how it may be useful for a wide range

149 and occurs at ambient temperature in aqueous DMF in an undivided cell open to air.

150 The addition of DMF in Fe(III/II)-IL does not change the structure of Fe

151 ur understanding of the proteins modified by DMF in human immune cells and the functional consequence

152 drug, our findings support a broader use of DMF in treatment of cancers and inflammatory conditions.

153 uggest that the antiinflammatory activity of DMF in treatment of MS patients may occur through altern

154 DMF in vitro treatment also led to increased T cell apop

155 To study the impact of DMF in vivo, we developed 2 CTCL xenograft mouse models

156 ction is performed in N,N-dimethylformamide (DMF) in a continuous membrane reactor which retains the

157 o explore the efficacy of dimethyl fumarate (DMF) in preventing disease reactivation after NTZ discon

158 number of decayed, missing, or filled teeth (dmfs) in caries-active children, number of episodes of p

159 After 3 y, dmfs increased in both groups (+12.9 INT vs. +10.8 UC; P

160 The dmfs increment was smaller among adherent INT children (

161 ver, 36% of the intervention effect on 24-mo DMFS increment was through a mediation effect on 12-mo o

162 decayed, missing, and filled tooth surfaces (dmfs) increment compared with UC.

163 In conclusion, NRF2 agonists 4-OI and DMF induce a distinct IFN-independent antiviral program

164 d the clinically approved dimethyl fumarate (DMF) induce a cellular antiviral program that potently i

165 DMF induced cell death in primary patient-derived CD4(+)

166 In addition, DMF induced increased cell death in primary CTCL tumors

167 DMF-induced cell death was linked specifically to NF-kap

168 Thus, DMF induces mitochondrial biogenesis primarily through i

169 ermeable thiol N-acetyl l-cysteine, reverses DMF inhibition of the NFkappaB pathway, supporting the n

170 In addition, DMF inhibits cell proliferation and significantly impair

171 In this study, we report that DMF inhibits human plasmacytoid dendritic cell function

172 the block in K63 and/or M1 chain formation, DMF inhibits NFkappaB and ERK1/2 activation, resulting i

173 We find that DMF inhibits pro-inflammatory cytokine production in res

174 have recently shown that dimethyl fumerate (DMF) inhibits NF-kappaB acting as a survival factor in C

175 To determine whether DMF interacts directly with p65, we synthesized and used

176 decayed, missing, and filled tooth surfaces (dmfs) (intercept) and rate of change in dmfs over time (

177 ormamidine (DMPF) and 2,4-dimethylformamide (DMF) into 2,4-dimethylaniline (DMA), directly from QuECh

178 As described herein, DMF-IP and P-CLIP-DMF-IP are rapid, automated, and multi

179 As described herein, DMF-IP and P-CLIP-DMF-IP are rapid, automated, and multiplexed methods tha

180 agnetic particles and digital microfluidics (DMF-IP).

181 show that DMFase from Paracoccus sp. strain DMF is a halophilic and thermostable enzyme comprising a

182 ent is of particular promise in CTCL because DMF is already in successful clinical use in the treatme

183 Given that DMF is an approved human therapeutic drug, our findings

184 The flexibility of DMF is compromised when devices are permanently modified

185 e in a counter-current membrane system where DMF is continuously replaced by ethanol.

186 se models, prompting us to determine whether DMF is effective as a treatment for SSc dermal fibrosis.

187 A unique hallmark of DMF is its "flexibility": a generic device design can be

188 One of the major benefits of DMF is that fluid motion and control is achieved without

189 Digital microfluidics (DMF) is a platform that enables highly reconfigurable an

190 Dimethyl fumarate (DMF) is a prescribed treatment for multiple sclerosis an

191 N,N-dimethyl formamide (DMF) is an extensively used organic solvent but is also

192 Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflamma

193 Dimethyl fumarate (DMF) is indicated for the treatment of relapsing multipl

194 In addition, 4-OI and DMF limit host inflammatory responses to SARS-CoV2 infec

195 and contributes to our understanding of how DMF may act clinically to ameliorate pathological proces

196 %) at moderate overpotentials (500-700 mV in DMF measured at the middle of the catalytic wave).

197 ngth was modulated from weak to strong (L' = DMF, MeCN, CN).

198 perties, both thermotropic and lyotropic (in DMF) mesophases were observed in one of metallacycles, i

199 ced in solvent of high dielectric constants (DMF), most likely by photoinduced electron transfer.

200 20 mg/kg per day intraperitoneally) or CsA + DMF (n = 7, 50 mg/kg per day orally) for 28 days.

201 enedicarboxylic acid, l-lac = l-lactic acid, dmf = N,N'-dimethylformamide) and observed an increase i

202 from the C-H bonds of N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-formylpyrrolidine (

203 DMF)2]H2O (BDC=benzene-1,4-dicarboxylate and DMF=N,N-dimethylformamide) under solvothermal conditions

204 s of the various areas that comprise the VLF-DMF network in learning rule-based cognitive selections

205 that the basic function expressed by the VLF-DMF network is to exert cognitive control of orofacial a

206 on experiments using polar solvents, such as DMF, no "mixed" products possessing structurally differe

207 In DMF, O-alkylation is faster than retroaldol-aldol rearra

208 Mean dmfs of those with caries in the intervention group was

209 al results demonstrate beneficial effects of DMF on key molecular pathways contributing to PAH, and s

210 examined and compared the effects of EP and DMF on MS-relevant activity/functions of T cells, macrop

211 the protective effects of dimethyl fumarate (DMF) on CsA-induced nephrotoxicity by enhancing the anti

212 vestigated the effects of dimethyl fumarate (DMF) on CTCL cells in vitro and in vivo.

213 olvent such as methanol, aqueous ethanol, or DMF or in biphasic mixtures that use acetonitrile.

214 ce were similar for patients with lesions in DMF or mOFC/vmPFC, compared with Controls.

215 -55) for EAE induction and treated with oral DMF or vehicle daily.

216 solvothermal reactions in dimethylformamide (dmf) or dimethylacetamide (dmac) with acetic acid or for

217 ces (dmfs) (intercept) and rate of change in dmfs over time (slope) was examined in 2-level linear mi

218 decayed, missing, or filled teeth surfaces (dmfs); pain; and extraction.

219 otocols, showing that such a system enhances DMF performance.

220 During the DMF phase, among the 39 patients, one or more relapses o

221 we present a free-standing, fully automated DMF platform for immunoassay.

222 imal geometry of the sensing surface and the DMF platform providing successful removal of the target

223 he optimum configuration is implemented on a DMF platform with an interdigitated capacitive biosensor

224 nto account the overall configuration of the DMF platform.

225 roheater array modularly integrated with the DMF platform.

226 face features that have been integrated on a DMF platform: a reagent delivery system and a thermal co

227 luidic and temperature control integrated on DMF platforms.

228 ofluidics and embedded sensors: "plug-n-play DMF" (PnP-DMF).

229 Dimethyl fumarate (DMF) possesses anti-inflammatory properties and is appro

230 Importantly, DMF prevented bleomycin-induced skin fibrosis in mice.

231 Mechanistically, DMF prevents p65 nuclear translocation and attenuates it

232 DMF protected WT and Nrf2(-/-) mice equally well from de

233 In mice, the administration of DMF protects against lipopolysaccharide shock and allevi

234 nally, we showed that chronic treatment with DMF reduced the firing of the ON cells (cells responding

235 y provides Class II evidence that first-line DMF reduces NFL in both blood and CSF after 6 months and

236 Digital microfluidics (DMF) represents an alternative to the conventional micro

237 quinolizinium) in CH3CN to 507 and 553 nm in DMF, respectively.

238 d distant metastasis-free survival (BCSS and DMFS, respectively).

239 s is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in pa

240 ondrial gene expression is more dependent on DMF's target Nrf2 than hydroxycarboxylic acid receptor 2

241 -free alkylation with methyl bromoacetate in DMF, saponification, and cyclization with acetic anhydri

242 We further showed that DMF significantly diminished nuclear TAZ/YAP localizatio

243 Upon soaking in a DMF solution of Cp2Co, the compound undergoes a single-c

244 as synthesized by heating dimethylformamide (DMF) solution of the known Ni-centered and Ni(CO)-capped

245 solution casting of their dimethylformamide (DMF) solutions under ambient conditions.

246 bonate, and mesitylenic acid as additives in DMF solvent.

247 er solvothermal conditions, from mixed water/DMF solvent.

248 The observation that DMF stimulates mitochondrial biogenesis, gene expression

249 The electrophilicity of DMF suggests that its immunosuppressive activity is rela

250 Mean DMF-T was significantly higher in patients with RA (19.3

251 decayed, missing, and/or filled adult teeth [DMF-T] index); 2) gingival inflammation (papillary bleed

252 ic acid esters, including dimethyl fumarate (DMF, Tecfidera; Biogen, Cambridge, MA), have shown thera

253 Dimethyl succinate, the inactive analog of DMF that lacks the electrophilic double bond of fumarate

254 te based ultramicroporous MOF, 1 [Ni-(4PyC)2.DMF], that has the lowest PE for postcombustion CO2 capt

255 ng reductive elimination at 140 degrees C in DMF to afford a beta-lactam product.

256 thways of further catalytic hydrogenation of DMF to N(CH(3))(3).

257 ion energy barriers during the conversion of DMF to N(CH(3))(3).

258 Coordination of DMF to the [((H)L)2Fe6] core leads to weaker Fe-Fe inter

259 Addition of DMA or DMF to the BGE impacts separation selectivity through di

260 Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the

261 7-expressing CD4(+) T cells were observed in DMF-treated patients.

262 DMF treatment delayed the growth of CTCL tumors and prev

263 s in vivo, we performed combined ABT-199 and DMF treatment in a xenograft mouse model for CTCL.

264 The beneficial effect of DMF treatment in Nrf2(-/-) and WT mice was accompanied b

265 However, DMF treatment in randomized controlled MS trials was ass

266 We show that DMF treatment is effective in reversing hemodynamic chan

267 DMF treatment is of particular promise in CTCL because D

268 ical and radiological activity preceding the DMF treatment might be used as a prognostic marker of th

269 the antiinflammatory contribution of Nrf2 in DMF treatment of the MS model, experimental autoimmune e

270 Our observations that oral DMF treatment promoted immune modulation and provided eq

271 Mechanistically, we found that DMF treatment reduced nuclear localization of transcript

272 In summary, DMF treatment represents a remarkable therapeutic option

273 number of relapses and MRI parameters before DMF treatment were good predictors of disease activity d

274 T cell activation was reduced with DMF treatment, especially among effector memory T cells

275 After 12 months of DMF treatment, NFL concentration decreased by 73%, 69% a

276 pression of ULBP2/5 and were unresponsive to DMF treatment, suggesting that the fumarate-stimulating

277 ory Th2 subset (CCR3(+)) was increased after DMF treatment.

278 sed and the CD4/CD8 ratio was increased with DMF treatment.

279 help to evaluate the efficacy and safety of DMF treatment.

280 o evidence of disease activity at the end of DMF treatment.

281 Finally, we demonstrate the ability of the DMF-TU molecular ink chemistry to lead to high-photovolt

282 is paper provides "proof of concept" for PnP-DMF using commercial biosensors for glucose and beta-ket

283 es a mechanism of the antifibrotic effect of DMF via inhibition of Akt1/GSK3beta/TAZ/YAP signaling an

284 By wave 4, the predicted mean difference in dmfs was 1.86 between children with low and normal birth

285 DMFS was analyzed as the primary end point, and RFS, OS,

286 hylacetamide (DMA) or N,N-dimethylformamide (DMF) was used to improve the separation selectivity.

287 entially binds with NR in dimethylformamide (DMF)/water (1:1) solution over other cations such as Fe(

288 duction of formic acid in dimethylformamide (DMF)/water mixtures (Faradaic efficiency of 90 +/- 10%)

289 In DMF/water (1:1, v/v), the receptor 1 showed a selectivit

290 first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL)

291 2 years of NTZ treatment and the 2 years of DMF were collected.

292 , missing and filled primary tooth surfaces (dmfs) were used as a repeated outcome measure.

293 pulation mechanism in digital microfluidics (DMF), where droplets can be actuated over a (super)hydro

294 fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gen

295 catalyzes electro-assisted H(2) evolution in DMF with distinct mechanisms depending on the strength o

296 ing the automated sample processing power of DMF with the resolving and analytical capacity of HPLC-M

297 e in-line coupling of digital microfluidics (DMF) with HPLC-MS, using a custom, 3D-printed manifold a

298 ination of CO2(*-) in N,N-dimethylformamide (DMF) with the tip generation/substrate collection (TG/SC

299 emiconductors, [Fe(tpma)(xbim)](X)(TCNQ)(1.5)DMF (X=ClO4(-) or BF4(-); tpma=tris(2-pyridylmethyl)amin

300 ral metal-organic framework [Zn2(bdc)(l-lac)(dmf)] (ZnBLD; bdc = 1,4-benzenedicarboxylic acid, l-lac